doi: 10.1111/cen.14421 55 ZhangHWangWZhaoJJiaoPZengLZhangHet al
Six observational studies have evaluated pregnancy outcomes after exposure to GLP-1 receptor agonists (GLP-1 RAs)
If more than 2 days have passed, then the patient should skip the missed dose and administer the next dose on the regularly scheduled day
Oral semaglutide has proven weight loss results and is further along in the approval process
This hormone prompts your body to release insulin, regulates blood sugar, and slows down stomach emptying to keep you feeling full longer
- Kurt thought there was a 50% chance all GLP-1 compounding would end in the next 6 months (both 503A and 503B) - Did not mention direct communication from the FDA telling them to stop compounding GLP-1s - ProRx felt it was time to stop due to the end of the shortage in March 2025, and did not feel influenced by the April 1 FDA statement - Kurt thinks 503B production of GLP-1s are underreported and much larger than thought - 503As can't take care of the compounded GLP-1 market at their current capacity - We both have concerns about patient access without compounded GLP-1s and worry it will send more patients to the grey market for RUO injections that don't have the same level of sterility and regulation To view or add a comment, sign in Every year, innovators rush into GLP studies before they're truly ready
